Award

Services to deliver Onasemnogene abeparvovec/Zolgensma

NHS ENGLAND - SPECIALISED COMMISSIONING

This public procurement record has 2 releases in its history.

Award

30 Jun 2021 at 14:23

Tender

02 Feb 2021 at 13:35

Summary of the contracting process

NHS England - Specialised Commissioning is seeking to commission a service for the delivery of Onasemnogene abeparvovec/Zolgensma, classified under health and social work services. The procurement, currently in the active tender stage, aims to engage four providers, potentially covering the North, Midlands, and South of England, alongside an additional provider. This tender process is based on an open procedure and is expected to span a duration of 1800 days, with the tender submission deadline set for 8th March 2021.

This procurement presents significant opportunities for businesses within the healthcare sector, particularly those specialising in gene therapy and paediatric care. Companies adept in managing complex treatment pathways, including those with experience in working with rare genetic disorders like spinal muscular atrophy, are well-suited to compete. Successful bidders must also have the capacity to comply with strict health regulations and demonstrate a commitment to quality service delivery as a key evaluation criterion.

Find more tenders on our Open Data Platform.
How relevant is this notice?

D3 Tenders Premium

Win More Public Sector Contracts

AI-powered tender discovery, pipeline management, and market intelligence — everything you need to grow your public sector business.

Notice Title

Services to deliver Onasemnogene abeparvovec/Zolgensma

Notice Description

NHS England is seeking to commission a service to deliver Onasemnogene abeparvovec/Zolgensma from four providers in England. It is currently anticipated that there may be one provider to cover the North of England, one to cover the Midlands, one to cover the South of England plus one other. The commissioner is by no means fixed on this geographical spread as the quality of the service provision is the most important factor.

Lot Information

Lot 1

Spinal muscular atrophy, or SMA, is a rare genetic disorder that causes muscle weakness and progressive loss of movement. It is most commonly caused by defects in the gene SMN1. Onasemnogene abeparvovec (Zolgensma, AveXis) is a single-use gene replacement therapy made of a viral vector that has been modified to contain the primary gene for the human survival motor neuron (SMN) protein, which is lacking or mutated in people with SMA. When injected, the vector is expected to carry the gene into the nerve cells, enabling production of sufficient amounts of SMN. It is administered intravenously. NHS England is seeking to commission a service to deliver Onasemnogene abeparvovec/Zolgensma from four providers in England. It is currently anticipated that there may be one provider to cover the North of England, one to cover the Midlands, one to cover the South of England plus one other. The commissioner is by no means fixed on this geographical spread as the quality of the service provision is the most important factor. As well as having a neuromuscular MDT and experience in treating children with SMA, the successful providers will need to have the capability to safely manage the product itself in line with it being classified as 'containment level 1' and ensure that all elements of the patient pathway (pre-treatment, during treatment and post-treatment) can be put into place. The providers will also be expected to operate as a national-MDT to ensure that eligible patients can be treated within appropriate timescales. This will involve regular meetings/calls to discuss the appropriate treatment of individual patients and to share information on capacity to treat patients. It is anticipated that the number of children requiring treatment each year is between 25 and 35, although this number may be subject to change, depending on the outcome of the NICE evaluation and, for example, if new-born screening for SMA was introduced. Novartis Gene Therapies is the company who produce this gene therapy and providers will be required to comply with the company's contractual documentation. This is currently in draft so providers will be expected to have contacted Novartis Gene Therapies prior to submitting a tender response to discuss their requirements in respect of providing a service to deliver Onasemnogene abeparvovec/Zolgensma. Given the significant amount of preparatory work that needs to be undertaken to deliver a gene therapy service, it is not feasible for commissioners and providers to wait until NICE has made its recommendation. To do so would risk the NHS not being ready to provide access within the timeframe set out in the Mandate requirements on NICE approved treatments and not being able to make the treatment available as soon as possible after the NICE decision has been made. Providers are therefore submitting bids to deliver a service 'at risk' and it may be the case that the product does not receive a positive NICE recommendation. Bidders are responsible for their own costs incurred throughout each stage of the Procurement process. Additional information: All bidders must complete the Qualification Questionnaire and Technical Questions.

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-028f59
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/014964-2021
Current Stage
Award
All Stages
Tender, Award

Procurement Classification

Notice Type
Tender Notice
Procurement Type
Standard
Procurement Category
Services
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

85 - Health and social work services


CPV Codes

85000000 - Health and social work services

85100000 - Health services

85140000 - Miscellaneous health services

Notice Value(s)

Tender Value
£6,000,000 £1M-£10M
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
£6,000,000 £1M-£10M

Notice Dates

Publication Date
30 Jun 20214 years ago
Submission Deadline
8 Mar 2021Expired
Future Notice Date
Not specified
Award Date
27 May 20214 years ago
Contract Period
Not specified - Not specified
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Cancelled
Awards Status
Active
Contracts Status
Active

Contracting Authority (Buyer)

Main Buyer
NHS ENGLAND - SPECIALISED COMMISSIONING
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LONDON
Postcode
SE1 6LH
Post Town
South East London
Country
England

Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI4 Inner London - East
Small Region (ITL 3)
TLI44 Lewisham and Southwark
Delivery Location
Not specified

Local Authority
Southwark
Electoral Ward
St George's
Westminster Constituency
Bermondsey and Old Southwark

Supplier Information

Number of Suppliers
4
Supplier Names

GUY’S AND ST THOMAS’ NHS FOUNDATION TRUST

MANCHESTER UNIVERSITY HOSPITALS FOUNDATION TRUST

SHEFFIELD CHILDREN’S NHS FOUNDATION TRUST

UNIVERSITY HOSPITALS BRISTOL AND WESTON NHS FOUNDATION TRUST

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

Download

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-028f59-2021-06-30T15:23:37+01:00",
    "date": "2021-06-30T15:23:37+01:00",
    "ocid": "ocds-h6vhtk-028f59",
    "initiationType": "tender",
    "tender": {
        "id": "ocds-h6vhtk-028f59",
        "legalBasis": {
            "id": "32014L0024",
            "scheme": "CELEX"
        },
        "title": "Services to deliver Onasemnogene abeparvovec/Zolgensma",
        "status": "complete",
        "classification": {
            "scheme": "CPV",
            "id": "85000000",
            "description": "Health and social work services"
        },
        "mainProcurementCategory": "services",
        "description": "NHS England is seeking to commission a service to deliver Onasemnogene abeparvovec/Zolgensma from four providers in England. It is currently anticipated that there may be one provider to cover the North of England, one to cover the Midlands, one to cover the South of England plus one other. The commissioner is by no means fixed on this geographical spread as the quality of the service provision is the most important factor.",
        "value": {
            "amount": 6000000,
            "currency": "GBP"
        },
        "lots": [
            {
                "id": "1",
                "description": "Spinal muscular atrophy, or SMA, is a rare genetic disorder that causes muscle weakness and progressive loss of movement. It is most commonly caused by defects in the gene SMN1. Onasemnogene abeparvovec (Zolgensma, AveXis) is a single-use gene replacement therapy made of a viral vector that has been modified to contain the primary gene for the human survival motor neuron (SMN) protein, which is lacking or mutated in people with SMA. When injected, the vector is expected to carry the gene into the nerve cells, enabling production of sufficient amounts of SMN. It is administered intravenously. NHS England is seeking to commission a service to deliver Onasemnogene abeparvovec/Zolgensma from four providers in England. It is currently anticipated that there may be one provider to cover the North of England, one to cover the Midlands, one to cover the South of England plus one other. The commissioner is by no means fixed on this geographical spread as the quality of the service provision is the most important factor. As well as having a neuromuscular MDT and experience in treating children with SMA, the successful providers will need to have the capability to safely manage the product itself in line with it being classified as 'containment level 1' and ensure that all elements of the patient pathway (pre-treatment, during treatment and post-treatment) can be put into place. The providers will also be expected to operate as a national-MDT to ensure that eligible patients can be treated within appropriate timescales. This will involve regular meetings/calls to discuss the appropriate treatment of individual patients and to share information on capacity to treat patients. It is anticipated that the number of children requiring treatment each year is between 25 and 35, although this number may be subject to change, depending on the outcome of the NICE evaluation and, for example, if new-born screening for SMA was introduced. Novartis Gene Therapies is the company who produce this gene therapy and providers will be required to comply with the company's contractual documentation. This is currently in draft so providers will be expected to have contacted Novartis Gene Therapies prior to submitting a tender response to discuss their requirements in respect of providing a service to deliver Onasemnogene abeparvovec/Zolgensma. Given the significant amount of preparatory work that needs to be undertaken to deliver a gene therapy service, it is not feasible for commissioners and providers to wait until NICE has made its recommendation. To do so would risk the NHS not being ready to provide access within the timeframe set out in the Mandate requirements on NICE approved treatments and not being able to make the treatment available as soon as possible after the NICE decision has been made. Providers are therefore submitting bids to deliver a service 'at risk' and it may be the case that the product does not receive a positive NICE recommendation. Bidders are responsible for their own costs incurred throughout each stage of the Procurement process. Additional information: All bidders must complete the Qualification Questionnaire and Technical Questions.",
                "contractPeriod": {
                    "durationInDays": 1800
                },
                "status": "cancelled",
                "awardCriteria": {
                    "criteria": [
                        {
                            "name": "Quality",
                            "type": "quality",
                            "description": "100"
                        },
                        {
                            "type": "price",
                            "description": "0"
                        }
                    ]
                },
                "hasOptions": false
            }
        ],
        "items": [
            {
                "id": "1",
                "additionalClassifications": [
                    {
                        "scheme": "CPV",
                        "id": "85100000",
                        "description": "Health services"
                    },
                    {
                        "scheme": "CPV",
                        "id": "85140000",
                        "description": "Miscellaneous health services"
                    }
                ],
                "deliveryAddresses": [
                    {
                        "region": "UK"
                    },
                    {
                        "region": "UK"
                    }
                ],
                "relatedLot": "1"
            }
        ],
        "submissionMethod": [
            "electronicSubmission",
            "written"
        ],
        "submissionMethodDetails": "https://uk.eu-supply.com/app/rfq/rwlentrance_s.asp?PID=36403&B=AGCSU",
        "otherRequirements": {
            "reductionCriteria": "As detailed within the ITT documents"
        },
        "procurementMethod": "open",
        "procurementMethodDetails": "Open procedure",
        "tenderPeriod": {
            "endDate": "2021-03-08T12:00:00Z"
        },
        "submissionTerms": {
            "languages": [
                "en"
            ]
        },
        "coveredBy": [
            "GPA"
        ]
    },
    "parties": [
        {
            "id": "GB-FTS-4052",
            "name": "NHS England - Specialised Commissioning",
            "identifier": {
                "legalName": "NHS England - Specialised Commissioning",
                "id": "na"
            },
            "address": {
                "streetAddress": "80 London Road",
                "locality": "London",
                "region": "UK",
                "postalCode": "SE1 6LH",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "name": "Anna Salt",
                "email": "anna.salt@nhs.net",
                "url": "https://uk.eu-supply.com/app/rfq/rwlentrance_s.asp?PID=36403&B=AGCSU"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "http://www.england.nhs.uk",
                "buyerProfile": "https://uk.eu-supply.com/ctm/Company/CompanyInformation/Index/68205",
                "classifications": [
                    {
                        "scheme": "TED_CA_TYPE",
                        "id": "BODY_PUBLIC",
                        "description": "Body governed by public law"
                    },
                    {
                        "scheme": "COFOG",
                        "id": "07",
                        "description": "Health"
                    }
                ]
            }
        },
        {
            "id": "GB-FTS-4053",
            "name": "Arden & GEM Commissioning Support Unit",
            "identifier": {
                "legalName": "Arden & GEM Commissioning Support Unit"
            },
            "address": {
                "streetAddress": "2nd Floor Cardinal Square, 10 Nottingham Road",
                "locality": "Derby",
                "postalCode": "DE1 3QT",
                "countryName": "United Kingdom"
            },
            "roles": [
                "reviewBody",
                "mediationBody",
                "reviewContactPoint"
            ]
        },
        {
            "id": "GB-FTS-21062",
            "name": "Manchester University Hospitals Foundation Trust",
            "identifier": {
                "legalName": "Manchester University Hospitals Foundation Trust"
            },
            "address": {
                "locality": "Manchester",
                "region": "UKD",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-21063",
            "name": "Guy's and St Thomas' NHS Foundation Trust",
            "identifier": {
                "legalName": "Guy's and St Thomas' NHS Foundation Trust"
            },
            "address": {
                "locality": "London",
                "region": "UKI",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-3327",
            "name": "Sheffield Children's NHS Foundation Trust",
            "identifier": {
                "legalName": "Sheffield Children's NHS Foundation Trust"
            },
            "address": {
                "locality": "Sheffield",
                "region": "UKE",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-21064",
            "name": "University Hospitals Bristol and Weston NHS Foundation Trust",
            "identifier": {
                "legalName": "University Hospitals Bristol and Weston NHS Foundation Trust"
            },
            "address": {
                "locality": "Bristol",
                "region": "UKK",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        }
    ],
    "buyer": {
        "id": "GB-FTS-4052",
        "name": "NHS England - Specialised Commissioning"
    },
    "language": "en",
    "awards": [
        {
            "id": "014964-2021-1-1",
            "relatedLots": [
                "1"
            ],
            "title": "Services to deliver Onasemnogene abeparvovec/Zolgensma",
            "status": "active",
            "suppliers": [
                {
                    "id": "GB-FTS-21062",
                    "name": "Manchester University Hospitals Foundation Trust"
                },
                {
                    "id": "GB-FTS-21063",
                    "name": "Guy's and St Thomas' NHS Foundation Trust"
                },
                {
                    "id": "GB-FTS-3327",
                    "name": "Sheffield Children's NHS Foundation Trust"
                },
                {
                    "id": "GB-FTS-21064",
                    "name": "University Hospitals Bristol and Weston NHS Foundation Trust"
                }
            ]
        }
    ],
    "contracts": [
        {
            "id": "014964-2021-1-1",
            "awardID": "014964-2021-1-1",
            "title": "Services to deliver Onasemnogene abeparvovec/Zolgensma",
            "status": "active",
            "value": {
                "amount": 6000000,
                "currency": "GBP"
            },
            "dateSigned": "2021-05-28T00:00:00+01:00"
        }
    ],
    "bids": {
        "statistics": [
            {
                "id": "1",
                "measure": "bids",
                "relatedLot": "1",
                "value": 11
            }
        ]
    }
}